Heron Therapeutics Inc banner

Intrinsic Value

The intrinsic value of Heron Therapeutics Inc (AXD2) under the Base Case is 2.49 EUR per share. Compared with the current market price of 0.23 EUR, the stock appears Undervalued by 91% .

The intrinsic value is calculated using valuation multiples.

Do our valuations actually work? See backtest results .

AXD2 Intrinsic Value
€2.49
Undervaluation 91%
Intrinsic Value
Price €0.23

AXD2 is cheaper than usual. This is its cheapest valuation in the past 5 years.

Alert me when AXD2 is below its intrinsic value
Today €1.99 · Already reached, the price is 88.5% below it
Alternatives to AXD2

Fundamental Analysis

What Heron Therapeutics Does

Biotechnology Health Care

Heron Therapeutics is a specialty pharmaceutical company that develops and sells prescription medicines used mainly in hospitals and clinics. Its drugs are aimed at problems tied to surgery and cancer care, especially pain control, nausea, and vomiting. In simple terms, Heron makes medicines that help patients feel better around medical procedures and other difficult treatments.

Headquarters
United States of America US
Employees
128
IPO date
Aug 26, 1987
Read the full company overview
View Company Overview
Financials

Balance Sheet

Efficiency

Wall St Price Targets

Shareholder Returns

Competitive Landscape

Recent Events

Past 12 months

Continue AXD2 Research

Decided on Heron Therapeutics? Get an email when AXD2 reaches the price you’d buy at. Free with an account.

Other Heron Therapeutics listings

What is the Intrinsic Value of one AXD2 stock?

The intrinsic value for Heron Therapeutics Inc (AXD2) under the Base Case is 2.49 EUR.

Is AXD2 stock undervalued or overvalued?

Compared with the current market price of 0.23 EUR, the stock appears Undervalued by 91% .

How reliable are our estimates? See how past valuations played out
Back to Top